Dose-Dense Paclitaxel Plus Carboplatin (PCdd) versus Epirubicin and Cyclophosphamide (ECdd) Followed by Paclitaxel (P) As Adjuvant Chemotherapy in Early Triple-Negative Breast Cancer at High Risk of Recurrence, A Randomised, Open-Label, Phase 3 Trial
Qing Li(Xiangnan University), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Fan(Academy of Medical Sciences), Jiayu Wang(East China Normal University), Qiao Li(Guangzhou University of Chinese Medicine), Yang Luo(Chongqing University of Posts and Telecommunications), Tongtong Zhang(Jiangsu Province Hospital), Pin Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiani Wang(Hubei University of Technology), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Han(Fujian University of Traditional Chinese Medicine), Yuxin Mu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 0
Related Papers
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
|Signal Transduction and Targeted Therapy|2019|406
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
|Chinese Journal of Cancer Research|2019|126
In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
|Frontiers in Oncology|2022|119
A More Universal Approach to Comprehensive Analysis of Thalassemia Alleles (CATSA)
|Journal of Molecular Diagnostics|2021|114